Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi
Yıl: 2022 Cilt: 6 Sayı: 2 Sayfa Aralığı: 45 - 49 Metin Dili: Türkçe DOI: 10.5578/llm.2022980 İndeks Tarihi: 27-10-2022
Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi
Öz: Amaç: Çalışmamızda yeni tanı, yüksek riskli diffüz büyük B-hücreli lenfoma (DBBHL) olgularında doz ayarlanmış EPOCH-R (DA-EPOCH-R) rejiminin sağkalım parametreleri üzerine etkisini araş- tırmayı amaçladık. Hastalar ve Yöntem: DBBHL hastalarının demografik, klinik özellikleriyle yanıt ve sağkalım para- metreleri geriye dönük olarak değerlendirildi. Bulgular: Çalışmaya medyan yaşı 49 (26-71) olan toplam 33 hasta (15 kadın, 18 erkek) dahil edildi. On yedi, on dört ve sekiz hastada sırasıyla evre III/IV hastalık, orta-yüksek/yüksek IPI skoru ve çift ifadeli lenfoma vardı. Yirmi altı hastada tam remisyon sağlandı. İki hasta sepsis nedeniyle kaybedildi. Tahmini progresyonsuz ve genel sağkalım sırasıyla 79.7 ± 8.418 (%95 CI= %63.21- 96.2) ve 90.87 ± 6.74 (%95 CI= %77.65-104.08) ay saptandı. Sonuç: DA-EPOCH-R yüksek riskli DBBHL olgularında etkin fakat toksik bir rejim
Anahtar Kelime: DA-EPOCH-R Experience In High-Risk Diffuse Large B-Cell Lymphoma
Öz: Objective: We aimed to evaluate the impact of dose-adjusted EPOCH-R (DA-EPOCH-R) regimen on outcome parameters in high-risk, newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. Patients and Methods: Demographic and clinical features, response and survival parameters of patients presenting with DLBCL were retrospectively analyzed. Results: The study included a total of 33 patients (15 women, 18 men) with a median age of 49 (26-71). Seventeen, fourteen and eight patients had stage III/IV, high-intermediate/high risk IPI and double expressor lymphoma, respectively. Twenty six patients achieved complete remission. Two patients died as a result of sepsis. Estimated progression-free and overall survival were 79.7 ± 8.418 (63.21-96.2%; 95% CI) and 90.87 ± 6.74 (77.65-104.08%; 95% CI) months, respectively. Conclusion: DA-EPOCH-R is an effective but toxic regimen in DLBCL patients presenting with high-risk features.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classifi- cation of lymphoid neoplasms. Blood 2016;127:2375-90. https:// doi.org/10.1182/blood-2016-01-643569
- 2. Coiffier B, Thieblemont C, van Den Neste E, Lepeu G, Planti- er I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing ritux- imab-CHOP to standard CHOP chemotherapy in DLBCL pa- tients: A study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040-5. https://doi.org/10.1182/ blood-2010-03-276246
- 3. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International trial (MInT) group. Lan- cet Oncol 2011;12:1013-22. https://doi.org/10.1016/S1470- 2045(11)70235-2
- 4. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A cancer and leukemia group B multi-center study of DA-EP- OCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758-65. https://doi.org/10.3324/haematol.2011.056531
- 5. Ziepert M, Haenclever D, Kuhnt E, Glass B, Schmitz N, Pfreund- schuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373- 80. https://doi.org/10.1200/JCO.2009.26.2493
- 6. Zhou Z, Sehn LH, Rademaker A, Gordon LI, Lacasce AS, Cros- by-Thompson A, et al. A enhanced international prognostic in- dex (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-42. https://doi. org/10.1182/blood-2013-09-524108
- 7. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostik Index: A risk model for CNS re- lapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2016;34:3150-6. https://doi.org/10.1200/ JCO.2015.65.6520
- 8. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of the diffuse large B-cell lymphoma by immunohistochemistry using tissue microarray. Blood 2004;103:275-82. https://doi. org/10.1182/blood-2003-05-1545
- 9. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwarz LH, Zucca E, et al. Rec-ommendations for the initial evaluation, staging and response assessment of Hodgkin and non- Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014;32(27):3059-68. https://doi.org/10.1200/JCO.2013.54.8800
- 10. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as front- line therapy for diffuse large B-cell lymphoma: clinical outcomes of phase III intergroup trial Alliance/CALGB 50303. J Clin Oncol 2019;37:1790-99. https://doi.org/10.1200/JCO.18.01994
- 11. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Shar - man JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl L Med 2022;386:351-63. https://doi.org/10.1056/NEJMoa2115304
- 12. Hu S, Xu-Monette Z, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferi- or survival of activated B-cell subtype of diffuse large B-cell lym- phoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consor- tium Program. Blood 2013;121:4021-31. https://doi.org/10.1182/ blood-2012-10-460063
- 13. Horn H, Ziepert M, Becher C, Barth TFE, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121:2253- 63. https://doi.org/10.1182/blood-2012-06-435842
- 14. Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial. J Clin Oncol 2018;36:2024-34. https:// doi.org/10.1200/JCO.2017.76.8093
| APA | AKPINAR S, Turgut B (2022). Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. , 45 - 49. 10.5578/llm.2022980 |
| Chicago | AKPINAR SEVAL,Turgut Burhan Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. (2022): 45 - 49. 10.5578/llm.2022980 |
| MLA | AKPINAR SEVAL,Turgut Burhan Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. , 2022, ss.45 - 49. 10.5578/llm.2022980 |
| AMA | AKPINAR S,Turgut B Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. . 2022; 45 - 49. 10.5578/llm.2022980 |
| Vancouver | AKPINAR S,Turgut B Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. . 2022; 45 - 49. 10.5578/llm.2022980 |
| IEEE | AKPINAR S,Turgut B "Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi." , ss.45 - 49, 2022. 10.5578/llm.2022980 |
| ISNAD | AKPINAR, SEVAL - Turgut, Burhan. "Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi". (2022), 45-49. https://doi.org/10.5578/llm.2022980 |
| APA | AKPINAR S, Turgut B (2022). Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, 6(2), 45 - 49. 10.5578/llm.2022980 |
| Chicago | AKPINAR SEVAL,Turgut Burhan Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları 6, no.2 (2022): 45 - 49. 10.5578/llm.2022980 |
| MLA | AKPINAR SEVAL,Turgut Burhan Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.6, no.2, 2022, ss.45 - 49. 10.5578/llm.2022980 |
| AMA | AKPINAR S,Turgut B Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları. 2022; 6(2): 45 - 49. 10.5578/llm.2022980 |
| Vancouver | AKPINAR S,Turgut B Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları. 2022; 6(2): 45 - 49. 10.5578/llm.2022980 |
| IEEE | AKPINAR S,Turgut B "Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi." Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, 6, ss.45 - 49, 2022. 10.5578/llm.2022980 |
| ISNAD | AKPINAR, SEVAL - Turgut, Burhan. "Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi". Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları 6/2 (2022), 45-49. https://doi.org/10.5578/llm.2022980 |
